Relafen 750, identified as naproxen, showcases a fascinating example within the biochemical pharmacy area. Its mode of operation primarily involves the preferential suppression of cyclooxygenase catalysts, specifically COX-2, resulting in a alleviation in inflammatory synthesis. From a therapeutic v